Arihiro Shiozaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Arihiro Shiozaki has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Shintaro Makino
Department of Obstetrics and Gynecology, Juntendo University Urayasu Hospital, Chiba, Japan
3 shared publications - Eri N. Arai
University of Toyama
2 shared publications - Hirohito Metoki
Tohoku Medical and Pharmaceutical University
2 shared publications - Hironobu Hyodo
Department of Obstetrics and Gynecology Tokyo Metropolitan Bokutoh Hospital Tokyo Japan
2 shared publications - Katsuhiko Naruse
Department of Obstetrics and Gynecology, Dokkyo Medical University, Tochigi, Japan
2 shared publications Mika Ito
University of Toyama
2 shared publications
Latest Publications
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5) , e047093
Prediction Model of Hypertensive Disorders of Pregnancy Based on Home Blood Pressure Monitoring
Background: Hypertensive disorders of pregnancy (HDP) cause adverse maternal and fetal outcomes, and establishing an early prediction method for HDP is needed. Existing methods based on serum markers require blood sampling. Therefore, we aimed to develop and validate a noninvasive HDP prediction model based on home blood pressure monitoring. Methods: In a development cohort, home blood pressure monitoring data from 443 pregnant women including 65 HDPs were divided into training data (n=365) and test data (n=78) to develop a logistic regression‐based prediction model. Normal blood pressure variations depending on season and gestational age were subtracted. At each time point, 4 features were calculated for the last 4 weeks of data: average systolic blood pressure, average diastolic blood pressure, correlation coefficient between systolic blood pressure and diastolic blood pressure, and upward trend of systolic blood pressure against day. In a validation cohort, HBPM data from 264 pregnant women including 33 HDPs were collected prospectively and used to validate the model. Results: The area under the receiver operating characteristic curve was 0.949 (95% CI, 0.890–1.000), 0.884 (95% CI, 0.807–0.961), and 0.845 (95% CI, 0.759–0.930) for the training, test, and validation data, respectively. Sensitivity, specificity, positive predictive value, and negative predictive value were 0.923, 0.888, 0.387, and 0.993 for the training data; 0.667, 0.897, 0.867, and 0.729 for the test data; 0.758, 0.766, 0.316, and 0.957 for the validation data. Conclusions: Our HDP prediction model based on home blood pressure monitoring showed high negative predictive values and may contribute to reducing medical consultations.
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5) , e047093
Prediction Model of Hypertensive Disorders of Pregnancy Based on Home Blood Pressure Monitoring
Background: Hypertensive disorders of pregnancy (HDP) cause adverse maternal and fetal outcomes, and establishing an early prediction method for HDP is needed. Existing methods based on serum markers require blood sampling. Therefore, we aimed to develop and validate a noninvasive HDP prediction model based on home blood pressure monitoring. Methods: In a development cohort, home blood pressure monitoring data from 443 pregnant women including 65 HDPs were divided into training data (n=365) and test data (n=78) to develop a logistic regression‐based prediction model. Normal blood pressure variations depending on season and gestational age were subtracted. At each time point, 4 features were calculated for the last 4 weeks of data: average systolic blood pressure, average diastolic blood pressure, correlation coefficient between systolic blood pressure and diastolic blood pressure, and upward trend of systolic blood pressure against day. In a validation cohort, HBPM data from 264 pregnant women including 33 HDPs were collected prospectively and used to validate the model. Results: The area under the receiver operating characteristic curve was 0.949 (95% CI, 0.890–1.000), 0.884 (95% CI, 0.807–0.961), and 0.845 (95% CI, 0.759–0.930) for the training, test, and validation data, respectively. Sensitivity, specificity, positive predictive value, and negative predictive value were 0.923, 0.888, 0.387, and 0.993 for the training data; 0.667, 0.897, 0.867, and 0.729 for the test data; 0.758, 0.766, 0.316, and 0.957 for the validation data. Conclusions: Our HDP prediction model based on home blood pressure monitoring showed high negative predictive values and may contribute to reducing medical consultations.
- Top Cited PapersOpen Access
- 15 October 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (16) , 1223-1235
Implementation of First-Trimester Screening and Prevention of Preeclampsia: A Stepped Wedge Cluster-Randomized Trial in Asia
BACKGROUND: This trial aimed to assess the efficacy, acceptability, and safety of a first-trimester screen-and-prevent strategy for preterm preeclampsia in Asia. METHODS: Between August 1, 2019, and February 28, 2022, this multicenter stepped wedge cluster randomized trial included maternity/diagnostic units from 10 regions in Asia. The trial started with a period where all recruiting centers provided routine antenatal care without study-related intervention. At regular 6-week intervals, one cluster was randomized to transit from nonintervention phase to intervention phase. In the intervention phase, women underwent first-trimester screening for preterm preeclampsia using a Bayes theorem-based triple-test. High-risk women, with adjusted risk for preterm preeclampsia ≥1 in 100, received low-dose aspirin from <16 weeks until 36 weeks. RESULTS: Overall, 88.04% (42 897 of 48 725) of women agreed to undergo first-trimester screening for preterm preeclampsia. Among those identified as high-risk in the intervention phase, 82.39% (2919 of 3543) received aspirin prophylaxis. There was no significant difference in the incidence of preterm preeclampsia between the intervention and non-intervention phases (adjusted odds ratio [aOR], 1.59 [95% CI, 0.91–2.77]). However, among high-risk women in the intervention phase, aspirin prophylaxis was significantly associated with a 41% reduction in the incidence of preterm preeclampsia (aOR, 0.59 [95% CI, 0.37–0.92]). In addition, it correlated with 54%, 55%, and 64% reduction in the incidence of preeclampsia with delivery at <34 weeks (aOR, 0.46 [95% CI, 0.23–0.93]), spontaneous preterm birth <34 weeks (aOR, 0.45 [95% CI, 0.22–0.92]), and perinatal death (aOR, 0.34 [95% CI, 0.12–0.91]), respectively. There was no significant between-group difference in the incidence of aspirin-related severe adverse events. CONCLUSIONS: The implementation of the screen-and-prevent strategy for preterm preeclampsia is not associated with a significant reduction in the incidence of preterm preeclampsia. However, low-dose aspirin effectively reduces the incidence of preterm preeclampsia by 41% among high-risk women. The screen-and-prevent strategy for preterm preeclampsia is highly accepted by a diverse group of women from various ethnic backgrounds beyond the original population where the strategy was developed. These findings underpin the importance of the widespread implementation of the screen-and-prevent strategy for preterm preeclampsia on a global scale. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03941886.
- 15 October 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (16) , 1223-1235
Top Cited PapersOpen AccessImplementation of First-Trimester Screening and Prevention of Preeclampsia: A Stepped Wedge Cluster-Randomized Trial in Asia
BACKGROUND: This trial aimed to assess the efficacy, acceptability, and safety of a first-trimester screen-and-prevent strategy for preterm preeclampsia in Asia. METHODS: Between August 1, 2019, and February 28, 2022, this multicenter stepped wedge cluster randomized trial included maternity/diagnostic units from 10 regions in Asia. The trial started with a period where all recruiting centers provided routine antenatal care without study-related intervention. At regular 6-week intervals, one cluster was randomized to transit from nonintervention phase to intervention phase. In the intervention phase, women underwent first-trimester screening for preterm preeclampsia using a Bayes theorem-based triple-test. High-risk women, with adjusted risk for preterm preeclampsia ≥1 in 100, received low-dose aspirin from <16 weeks until 36 weeks. RESULTS: Overall, 88.04% (42 897 of 48 725) of women agreed to undergo first-trimester screening for preterm preeclampsia. Among those identified as high-risk in the intervention phase, 82.39% (2919 of 3543) received aspirin prophylaxis. There was no significant difference in the incidence of preterm preeclampsia between the intervention and non-intervention phases (adjusted odds ratio [aOR], 1.59 [95% CI, 0.91–2.77]). However, among high-risk women in the intervention phase, aspirin prophylaxis was significantly associated with a 41% reduction in the incidence of preterm preeclampsia (aOR, 0.59 [95% CI, 0.37–0.92]). In addition, it correlated with 54%, 55%, and 64% reduction in the incidence of preeclampsia with delivery at <34 weeks (aOR, 0.46 [95% CI, 0.23–0.93]), spontaneous preterm birth <34 weeks (aOR, 0.45 [95% CI, 0.22–0.92]), and perinatal death (aOR, 0.34 [95% CI, 0.12–0.91]), respectively. There was no significant between-group difference in the incidence of aspirin-related severe adverse events. CONCLUSIONS: The implementation of the screen-and-prevent strategy for preterm preeclampsia is not associated with a significant reduction in the incidence of preterm preeclampsia. However, low-dose aspirin effectively reduces the incidence of preterm preeclampsia by 41% among high-risk women. The screen-and-prevent strategy for preterm preeclampsia is highly accepted by a diverse group of women from various ethnic backgrounds beyond the original population where the strategy was developed. These findings underpin the importance of the widespread implementation of the screen-and-prevent strategy for preterm preeclampsia on a global scale. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03941886.
- Top Cited Papers
- 17 October 2022
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 49 (1) , 5-53
Guidelines for obstetrical practice in Japan: Japan Society of Obstetrics and Gynecology and Japan Association of Obstetricians and Gynecologists 2020 edition
The 2017 clinical guidelines for obstetrical practice by the Japan Society of Obstetrics and Gynecology and the Japan Association of Obstetricians and Gynecologists were revised and published as the 2020 edition (in Japanese). The aim of these guidelines is to present appropriate standard obstetric diagnosis and management procedures that have reached consensus among Japanese obstetricians. The 2020 guidelines include 113 clinical questions and an appendix, followed by answers (CQ&A; originally 112 in the 2017 edition), a discussion, list of references, and some tables and figures presenting common problems and questions encountered in obstetrical practice. Each answer comes with a recommendation level of A, B, or C and has been prepared based principally on evidence or a consensus among Japanese obstetricians in situations where “evidence” is weak or lacking. Answers with a recommendation level of A or B represent current standard care practices in Japan. All 113 CQ&As and the appendix are presented here to promote a better understanding of the current standard care practices for pregnant and lactating women in Japan.
- 17 October 2022
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 49 (1) , 5-53
Top Cited PapersGuidelines for obstetrical practice in Japan: Japan Society of Obstetrics and Gynecology and Japan Association of Obstetricians and Gynecologists 2020 edition
The 2017 clinical guidelines for obstetrical practice by the Japan Society of Obstetrics and Gynecology and the Japan Association of Obstetricians and Gynecologists were revised and published as the 2020 edition (in Japanese). The aim of these guidelines is to present appropriate standard obstetric diagnosis and management procedures that have reached consensus among Japanese obstetricians. The 2020 guidelines include 113 clinical questions and an appendix, followed by answers (CQ&A; originally 112 in the 2017 edition), a discussion, list of references, and some tables and figures presenting common problems and questions encountered in obstetrical practice. Each answer comes with a recommendation level of A, B, or C and has been prepared based principally on evidence or a consensus among Japanese obstetricians in situations where “evidence” is weak or lacking. Answers with a recommendation level of A or B represent current standard care practices in Japan. All 113 CQ&As and the appendix are presented here to promote a better understanding of the current standard care practices for pregnant and lactating women in Japan.
- 26 January 2022
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 48 (3) , 688-693
Probiotics including Clostridium butyricum, Enterococcus faecium, and Bacillus subtilis may prevent recurrent spontaneous preterm delivery
Aim: A large cohort study of Japanese women reported that the rate of recurrent spontaneous preterm delivery (sPTD) in the next pregnancy was 22.3%; therefore, it is important to prevent recurrent sPTD. The present study investigated the rate of recurrent sPTD in pregnant women treated with probiotics.Methods: This was a retrospective study. Fifty‐one pregnant women with a history of sPTD and who had been taking probiotics before 14 weeks of gestation were selected. The rate of sPTD in the next pregnancy among 255 pregnant women with a history of sPTD who had not taken probiotics was compared with that in the probiotics group.Results: The rate of recurrent sPTD was 9.8% (5/51), which was lower than previously reported values. Furthermore, the rate of recurrent sPTD was significantly lower in the probiotics group (9.8%) than in the nonprobiotics group (31.0% [79/255]; p = 0.002).Conclusions: Probiotics may reduce the rate of recurrent sPTD.
- 26 January 2022
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 48 (3) , 688-693
Probiotics including Clostridium butyricum, Enterococcus faecium, and Bacillus subtilis may prevent recurrent spontaneous preterm delivery
Aim: A large cohort study of Japanese women reported that the rate of recurrent spontaneous preterm delivery (sPTD) in the next pregnancy was 22.3%; therefore, it is important to prevent recurrent sPTD. The present study investigated the rate of recurrent sPTD in pregnant women treated with probiotics.Methods: This was a retrospective study. Fifty‐one pregnant women with a history of sPTD and who had been taking probiotics before 14 weeks of gestation were selected. The rate of sPTD in the next pregnancy among 255 pregnant women with a history of sPTD who had not taken probiotics was compared with that in the probiotics group.Results: The rate of recurrent sPTD was 9.8% (5/51), which was lower than previously reported values. Furthermore, the rate of recurrent sPTD was significantly lower in the probiotics group (9.8%) than in the nonprobiotics group (31.0% [79/255]; p = 0.002).Conclusions: Probiotics may reduce the rate of recurrent sPTD.
- Open Access
- 30 November 2017
- Published by Japan Society for the Study of Hypertension in Pregnancy in Hypertension Research in Pregnancy
- Vol. 5 (2) , 36-38
Home blood pressure measurement (HBPM) for the early detection of hypertensive disorders of pregnancy (HDP) in Japanese women: a multicenter prospective study
A multicenter study on home blood pressure measurement (HBPM) targeting Japanese pregnant women by the Japan Society for the Study of Hypertension in Pregnancy (JSSHP) has been ongoing since 2016. To date, over 200 pregnant women have been enrolled. This is an interim report.
- 30 November 2017
- Published by Japan Society for the Study of Hypertension in Pregnancy in Hypertension Research in Pregnancy
- Vol. 5 (2) , 36-38
Open AccessHome blood pressure measurement (HBPM) for the early detection of hypertensive disorders of pregnancy (HDP) in Japanese women: a multicenter prospective study
A multicenter study on home blood pressure measurement (HBPM) targeting Japanese pregnant women by the Japan Society for the Study of Hypertension in Pregnancy (JSSHP) has been ongoing since 2016. To date, over 200 pregnant women have been enrolled. This is an interim report.